F2G

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections.

The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals.

Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.